Veracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis

Veracyte, Inc. (NASDAQ: VCYT) announced that data confirming the analytical validity of the company’s Envisia™ Genomic Classifier have been published online in the journal BMC Pulmonary Medicine. The findings add to the growing body of evidence, including previously reported clinical validity and clinical utility data, supporting the use of the Envisia classifier to enable diagnosis of idiopathic pulmonary fibrosis (IPF), without the need for invasive, risky and costly surgical procedures.

“These new data underscore the scientific rigor behind the Envisia Genomic Classifier and should give physicians and their patients even more confidence in the test’s results,” said Giulia C. Kennedy, Ph.D., chief scientific officer of Veracyte. “By providing information that until now could only be obtained through diagnostic surgery, the Envisia classifier should help patients with suspected IPF get clearer answers faster so that they can receive the treatment they need – and avoid potentially harmful invasive procedures.”

In the new study, Veracyte researchers found that the Envisia classifier’s performance demonstrated highly accurate, reproducible, and reliable results across a range of laboratory conditions and variables. This included the stability of patient samples during collection, shipment and storage, as well as consistent test performance despite variations in RNA quantity and potential blood and DNA contamination, which may occur in routine clinical practice. The study also showed that the test’s results were reproducible across operators, processing runs, reagent lots and laboratories.

About the Envisia Genomic Classifier

The Envisia Genomic Classifier provides answers that improve physicians' ability to differentiate idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs) without the need for invasive, risky and costly surgery. The 190-gene classifier employs RNA sequencing to provide the core information needed by physicians to make an ILD diagnosis, using samples obtained through less-invasive bronchoscopy. The test is designed to provide information that was previously only available through surgical lung biopsy and by expert pathology review. Veracyte believes that the use of the Envisia classifier can provide a new standard of care for IPF patients, reducing the number of surgeries in IPF diagnosis, speeding the time to diagnosis and saving healthcare costs.